Searchable abstracts of presentations at key conferences in endocrinology

ea0006p37 | Endocrine tumours and neoplasia | SFE2003

Normalisation of serum IGF-I by pegvisomant is not associated with a reduction in median nerve size in patients with active acromegaly

Drake W , Loureira R , Besser G , Monson J , Trainer P , Reznek R , Sohaib S

Carpal tunnel syndrome (CTS) in acromegaly is caused, in part, by median nerve (MN) swelling. Pegvisomant (Peg), a growth hormone receptor (GHR) antagonist, lowers serum insulin-like growth factor-I (IGF-I) concentrations in patients with acromegaly, but serum GH levels rise and Peg is detected by most GH assays. Demonstrating that normalisation of serum IGF-I by Peg is associated with improvement/reversal of the consequences of GH excess is desirable. We documented changes in...